Global pharmaceutical company Eli Lilly and Company (NYSE: LLY) announced on Tuesday that it is planning to build a new manufacturing facility at Generation Park in Houston, Texas.

Expected to be operational within five years, the USD6.5bn facility will focus on producing Lilly's pipeline of small molecule medicines across therapeutic areas, including cardiometabolic health, oncology, immunology and neuroscience.

The Houston site will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of 2025.